{"log_id": 4780841964339125218, "direction": 0, "words_result_num": 31, "words_result": [{"probability": {"variance": 0, "average": 0.999804, "min": 0.999559}, "location": {"width": 168, "top": 182, "height": 27, "left": 153}, "words": "机构进行医疗随访"}, {"probability": {"variance": 0.016303, "average": 0.941645, "min": 0.656144}, "location": {"width": 109, "top": 233, "height": 24, "left": 164}, "words": "〖药理毒理】"}, {"probability": {"variance": 0, "average": 0.999457, "min": 0.998728}, "location": {"width": 85, "top": 281, "height": 27, "left": 155}, "words": "药理作用"}, {"probability": {"variance": 0.010714, "average": 0.962157, "min": 0.591941}, "location": {"width": 587, "top": 315, "height": 44, "left": 155}, "words": "药物治疗分类:精神兴奋剂,其他抗抑郁药,ATC-码:NO6AX21"}, {"probability": {"variance": 0.005943, "average": 0.977751, "min": 0.496146}, "location": {"width": 877, "top": 354, "height": 48, "left": 194}, "words": "阿戈美拉汀是褪黑素受体激动剂(MT1和MT2受体)和5-HT2c受体拮抗剂。动物研究结果显示"}, {"probability": {"variance": 1.1e-05, "average": 0.998629, "min": 0.979906}, "location": {"width": 934, "top": 400, "height": 52, "left": 153}, "words": "阿戈美拉汀能校正昼夜节律紊乱动物模型的昼夜节律,使节律得以重建。阿戈美拉汀在多种抑郁症动物"}, {"probability": {"variance": 1e-06, "average": 0.999151, "min": 0.997494}, "location": {"width": 234, "top": 468, "height": 30, "left": 156}, "words": "模型中显示出抗抑郁作用"}, {"probability": {"variance": 6.8e-05, "average": 0.997589, "min": 0.945782}, "location": {"width": 890, "top": 496, "height": 50, "left": 197}, "words": "阿戈美拉汀能特异性地增加前额皮质去甲肾上腺素和多巴胺的释放,而对细胞外五羟色胺水平没有"}, {"probability": {"variance": 6.9e-05, "average": 0.995939, "min": 0.967961}, "location": {"width": 931, "top": 543, "height": 51, "left": 157}, "words": "影响。受体结合试验结果显示,阿戈美拉汀对单胺再摄取无明显影响,对a、β肾上腺素受体、组胺受"}, {"probability": {"variance": 1.1e-05, "average": 0.998577, "min": 0.983815}, "location": {"width": 569, "top": 600, "height": 42, "left": 158}, "words": "体、胆碱受体、多巴胺受体以及苯二氮卓类受体无明显亲和力"}, {"probability": {"variance": 1e-06, "average": 0.999239, "min": 0.995699}, "location": {"width": 891, "top": 639, "height": 50, "left": 200}, "words": "人体研究中,阿戈美拉汀对睡眠具有正向的时相调整作用,诱导睡眠时相提前,降低体温,引发类"}, {"probability": {"variance": 2e-06, "average": 0.997879, "min": 0.995872}, "location": {"width": 107, "top": 709, "height": 26, "left": 159}, "words": "褪黑素作用"}, {"probability": {"variance": 1e-06, "average": 0.999161, "min": 0.997865}, "location": {"width": 85, "top": 757, "height": 24, "left": 160}, "words": "毒理研究"}, {"probability": {"variance": 5e-06, "average": 0.9976, "min": 0.994453}, "location": {"width": 87, "top": 802, "height": 27, "left": 212}, "words": "遗传毒性"}, {"probability": {"variance": 0.000249, "average": 0.996443, "min": 0.895444}, "location": {"width": 891, "top": 828, "height": 52, "left": 199}, "words": "阿戈美拉汀Ames试验、小鼠淋巴瘤细胞基因突变试验、人外周血淋巴细胞遗传学试验、程序外"}, {"probability": {"variance": 0.000198, "average": 0.993402, "min": 0.934609}, "location": {"width": 452, "top": 889, "height": 40, "left": 160}, "words": "DNA合成(UDS)试验、微核试验结果均为阴性"}, {"probability": {"variance": 2.8e-05, "average": 0.996321, "min": 0.987248}, "location": {"width": 87, "top": 946, "height": 26, "left": 213}, "words": "生殖毒性"}, {"probability": {"variance": 2.8e-05, "average": 0.996731, "min": 0.979125}, "location": {"width": 889, "top": 973, "height": 50, "left": 204}, "words": "阿戈美拉汀在经口给药剂量低于240mgkg时对雌性和雄性大鼠的生育力未见影响( NOAEL),在"}, {"probability": {"variance": 8e-05, "average": 0.996713, "min": 0.955064}, "location": {"width": 930, "top": 1020, "height": 52, "left": 163}, "words": "此剂量下动物暴露量比人用剂量25mg时暴露量高300倍。胚胎胎仔发育毒性试验中,大鼠中阿戈美拉"}, {"probability": {"variance": 0.000535, "average": 0.992535, "min": 0.867173}, "location": {"width": 912, "top": 1068, "height": 52, "left": 163}, "words": "汀剂量高至640mg/kg时未见胚胎毒性和致畸性;家兔剂量高至450mg/kg时未见胚胎毒性和致畸性"}, {"probability": {"variance": 3.6e-05, "average": 0.997809, "min": 0.962692}, "location": {"width": 928, "top": 1115, "height": 53, "left": 166}, "words": "上述剂量母体暴露量大约分别是人用剂量25mg时暴露量的720和300倍。大鼠围产期毒性试验中,在"}, {"probability": {"variance": 0.001215, "average": 0.538394, "min": 0.503534}, "location": {"width": 54, "top": 1156, "height": 26, "left": 956}, "words": " L Gr"}, {"probability": {"variance": 1e-05, "average": 0.99843, "min": 0.987013}, "location": {"width": 611, "top": 1171, "height": 45, "left": 164}, "words": "母体暴露量为人用剂量25mg时暴露量的280倍时,未见明显异常"}, {"probability": {"variance": 6e-06, "average": 0.998795, "min": 0.984855}, "location": {"width": 889, "top": 1212, "height": 49, "left": 208}, "words": "未见阿戈美拉汀对幼年动物的行为表现,视觉和生殖功能的影响。观察到与药理作用相关的轻度"}, {"probability": {"variance": 5e-06, "average": 0.998943, "min": 0.987439}, "location": {"width": 867, "top": 1259, "height": 54, "left": 166}, "words": "非剂量依赖型体重下降,同时观察到对雄性生殖道有微小影响,但对生殖能力没有损害"}, {"probability": {"variance": 0, "average": 0.999943, "min": 0.999901}, "location": {"width": 67, "top": 1327, "height": 26, "left": 217}, "words": "致癌性"}, {"probability": {"variance": 0.000569, "average": 0.992862, "min": 0.820883}, "location": {"width": 890, "top": 1354, "height": 49, "left": 209}, "words": "大鼠与小鼠分别经口给予本品40、120、360mgkg或125、500、2000mg/kg,连续104周,按暴"}, {"probability": {"variance": 0.001217, "average": 0.989105, "min": 0.752412}, "location": {"width": 929, "top": 1401, "height": 51, "left": 167}, "words": "露量计算分别相当于人用剂量25mg时暴露量的7.5、22、110倍或5、10、47.5倍。大鼠中,剂量≥120"}, {"probability": {"variance": 0.005934, "average": 0.976367, "min": 0.532259}, "location": {"width": 933, "top": 1451, "height": 54, "left": 167}, "words": "mg/kg的雄性动物肝腺瘤发生率增加,360mg/kg剂量组雄性动物肝癌发生率增加;小鼠中,500、2000"}, {"probability": {"variance": 1e-05, "average": 0.997905, "min": 0.982642}, "location": {"width": 758, "top": 1502, "height": 51, "left": 166}, "words": "mgkg剂量组肝腺瘤发生率增加,2000mgkg剂量下雌雄动物的肝癌的发生率增加"}, {"probability": {"variance": 5.5e-05, "average": 0.994733, "min": 0.978363}, "location": {"width": 135, "top": 1565, "height": 27, "left": 175}, "words": "【药代动力学】"}], "language": 3}